Answers are grounded in this paper and cite their sources.
This viewpoint discusses the use of blood-based biomarkers for Alzheimer disease, highlighting potential risks and necessary actions to improve care.
This Viewpoint discusses areas of potential harm and actions needed to mitigate risk so that the use of blood-based biomarkers for Alzheimer disease can achieve the intended goal of improving care for all.
No takes yet. Share an insight, caveat, or question.
Whitson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: